TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sana Biotechnology ( (SANA) ) has provided an announcement.
On August 6, 2025, Sana Biotechnology, Inc. announced the pricing of its public offering of 20,895,522 shares of common stock at $3.35 per share and pre-funded warrants for 1,492,537 shares at $3.3499 per share. The offering, expected to close on August 8, 2025, aims to raise approximately $70 million in net proceeds, enhancing Sana’s financial position and potentially impacting its market operations.
The most recent analyst rating on (SANA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Sana Biotechnology stock, see the SANA Stock Forecast page.
Spark’s Take on SANA Stock
According to Spark, TipRanks’ AI Analyst, SANA is a Underperform.
Sana Biotechnology’s overall stock score is primarily impacted by significant financial challenges, including consistent losses and a lack of revenue. Despite some improvements in balance sheet stability and operating cash flow, the bearish technical indicators and negative valuation metrics underscore the need for strategic changes to achieve growth and profitability.
To see Spark’s full report on SANA stock, click here.
More about Sana Biotechnology
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients, with operations in Seattle, WA, Cambridge, MA, and South San Francisco, CA.
Average Trading Volume: 4,969,070
Technical Sentiment Signal: Hold
Current Market Cap: $960.9M
See more data about SANA stock on TipRanks’ Stock Analysis page.